Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human HER2 monoclonal antibody vs Herceptin in HER2-positive metastatic breast cancer
CTR20170516Phase 3Completed
- Sponsor
- Anke Bio
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab in HER2-positive breast cancer, sponsored by Anke Bio. Started May 2019; status: completed.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on CTR20170516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170516.